Report Description
A recent market
intelligence report that is published by Data Insights Partner on Plasma
Fractionation market makes an offering of in-depth analysis of segments and
sub-segments in the regional and international Plasma Fractionation market. The research
also emphasizes on the impact of restraints, drivers, and macro indicators on
the regional and world Plasma Fractionation market over the short
as well as long period of time. A detailed presentation of forecast, trends,
and dollar values of international Plasma Fractionation market is offered. In accordance with the report, the global Plasma
Fractionation market is projected to
expand at a CAGR of 6% over the period
of forecast.
Market Insight, Drivers, Restraints&
Opportunity of the Market:
Plasma
fractionation is the process which separates of blood components from blood
plasma. Million of liters of plasma (raw materials) is required annually to
produce plasma derived products. Some of the
plasma is obtained by separating plasma from red blood cells after whole
blood donation, for example at a blood donation camp. This plasma is known as
“recovered plasma” because the target of the blood donation camps is to get red
cells, platelets and plasma (by products). Another type of plasma is known as
source plasma which is achieved from specialized plasma donation center through
plasmapheresis instrument (which obtains the whole blood from the donor, keep
the plasma and return the red cells to the donors).
The global Plasma Fractionation market is driven by the increasing
geriatric population, growing use of immunoglobulins in therapeutic areas,
growing new cases of complicated disease, and growth of plasma collection. Increasing
prevalence of complicated diseases such as pancreatic cancer, hemophilia, Von
Willebrand disease etc. primarily would likely to drive the global plasma
fractionation market. Pancreatic cancer is recognized as the fourth leading
cause of death in the U.S. In 2010, the rate of death from pancreatic cancer in
the U.S. was around 40,000 which would likely to increase to 60,000 in 2020.
Plasma profiling is one of the effective diagnosis method for pancreatic
cancer. Plasma proteins are also significant biomarkers for studying breast
cancer.
On the other hand, pricing pressure and stringent
regulatory condition may hamper the growth of the global plasma fractionation
market during the forecast period. Currently major companies express their
concerns about the growing pricing pressure in Europe and North America. Higher
price is due to the increasing raw material cost, cost of products and
inventory used for production of plasma derived proteins. According to the
annual report of China Biologic, the cost of raw material is about to 80% of
the total inventory cost. Increasing
R&D investment and strategic alliance by the major companies would provide
the global Plasma Fractionation market an opportunity to grow during the
forecast period. CSL Limited, one of the
reputed companies in the global plasma fractionation market increased the
research and development by 5% in 2017 compared to the R&D investment in
2016 and Octaphamra AG, Germany based company increased R&D investment by
23% in 2017 as compared to R&D investment in 2016.
Segment Covered:
This market
intelligence report on the global Plasma Fractionation Market encompasses
market segments based on product type, end-user and geography. On the basis of product
type, the sub-markets is segmented into Polyvalent IVIG, Polyvalent IVIG/SCIG, Factor
VIII, Factor IX, PCC, Fibrinogen Conc., Factor XIII, VWF, Albumin, Fresh Frozen
Plasma and Others. In terms of application, the global Plasma Fractionation
market is divided into neurology, immunology, hematology, critical care and
others. By end user, the global Plasma Fractionation market is categorized into
hospitals, biotechnology and pharmaceutical industry, clinical research
laboratories and others. By Geography, the global Plasma Fractionation market has been divided into North America
(the U.S., Canada), Latin America (Brazil, Mexico, Argentina and other
countries), Europe (Germany, France, the U.K., Spain, Italy, Russia, and other
countries), Asia Pacific (India, Japan, China, Australia and New Zealand and
other countries), Middle East and Africa (GCC, South Africa, Israel and Other
countries).
Profiling of Market
Players:
This business
intelligence report offers profiling of reputed companies that are operating in
the market. Companies such as CSL Limited, Grifols, S.A., Baxter, Octapharma,
Kedrion S.p.A, Biotest AG, Albumedix, China Biologic Products Holdings,
Inc, The LFB Group, etc. among others
have been profiled into detail so as to offer a glimpse of the market leaders.
Moreover, parameters such as Plasma Fractionation market related investment
& spending and developments by major players of the market are tracked in
this global report.
Report Highlights:
In-depth
analysis of the micro and macro indicators, market trends, and forecasts of
demand is offered by this business intelligence report. Furthermore, the report
offers a vivid picture of the factors that are steering and restraining the
growth of this market across all geographical segments. In addition to that, IGR-Growth
Matrix analysis is also provided in the report so as to share insight of the
investment areas that new or existing market players can take into consideration.
Various analytical tools such as DRO analysis, Porter's five forces analysis
has been used in this report to present a clear picture of the market. The
study focuses on the present market trends and provides market forecast from
the year 2017-2027. Emerging trends that would shape the market demand in the
years to come have been highlighted in this report. A competitive analysis in
each of the geographical segments gives an insight into market share of the
global players.
Salient Features:
Ø
This study offers
comprehensive yet detailed analysis of the Plasma Fractionation market, size of the market (US$ Mn), and Compound Annual Growth
Rate (CAGR (%)) for the period of forecast: 2019 – 2027, taking into account
2018 as the base year
Ø
It explains upcoming
revenue opportunities across various market segments and attractive matrix of
investment proposition for the said market
Ø
This market
intelligence report also offers pivotal insights about various market opportunities,
restraints, drivers, launch of new products, competitive market strategies of
leading market players, emerging market trends, and regional outlook
Ø
Profiling of
key market players in the world Plasma Fractionation market is done by taking into account various parameters such as
company strategies, distribution strategies, product portfolio, financial
performance, key developments, geographical presence, and company overview
Ø
Leading
market players covered this report comprise names such as CSL Limited, Grifols, S.A., Baxter, Octapharma, Kedrion
S.p.A, Biotest AG, Albumedix, China Biologic Products Holdings, Inc, and The
LFB Group
Ø
The data of
this report would allow management authorities and marketers of companies alike
to take informed decision when it comes to launch of products, government
initiatives, marketing tactics and expansion, and technical up gradation
Ø
The world
market for Plasma Fractionation market caters to the needs of various stakeholders pertaining to
this industry, namely suppliers, manufacturers, investors, and distributors for
Plasma
Fractionation market. The research also caters to the rising needs
of consulting and research firms, financial analysts, and new market entrants
Ø
Research
methodologies that have been adopted for the purpose of this study have been
clearly elaborated so as to facilitate better understanding of the reports
Ø
Reports have
been made based on the guidelines as mandated by General Data Protection
Regulation
Ø
Ample number
of examples and case studies have been taken into consideration before coming
to a conclusion
Reasons to buy:
v
Identify
opportunities and plan strategies by having a strong understanding of the
investment opportunities in the Plasma Fractionation market
v
Identification
of key factors driving investment opportunities in the Plasma
Fractionation market
v
Facilitate
decision-making based on strong historic and forecast data
v
Position
yourself to gain the maximum advantage of the industry’s growth potential
v
Develop
strategies based on the latest regulatory events
v
Identify key
partners and business development avenues
v
Respond to
your competitors’ business structure, strategy and prospects
v
Identify key
strengths and weaknesses of important market participants